Rheonix, Inc

Rheonix, Inc

Improving standards of care by making molecular diagnostics available to more people, in more places, more often.

Founded 2007

Ithaca, United States 27 employees Convertible Note Total: $86.72M Biotechnology, Health Care +2

Rheonix is a biotechnology startup with a mission to improve standards of care by making molecular diagnostics more accessible. Founded in 2007 and headquartered in the United States, Rheonix has developed the Encompass platform, a highly customizable technology designed to simplify processes and enhance innovation in the field of molecular diagnostics. The platform, which operates on the Rheonix CARD® cartridge, enables fully automated, complex molecular assays in an easy-to-use and cost-effective format. With a focus on privacy and security, Rheonix is positioned to penetrate various key market sectors, including reference labs through point-of-care and everywhere in-between. Notably, the company received a Convertible Note investment on 13 February 2019 from Advantage Capital Partners, signifying confidence from a prominent investor in the future potential of Rheonix. With its commitment to expanding access to molecular diagnostics, Rheonix represents an innovative player in the evolving landscape of healthcare technology.

Funding Stage	Amount	Investors	Lead Investors	Date
Convertible Note	Undisclosed	1	Advantage Capital Partners	13 Feb 2019
Venture Round	$28.60M	6	Advantage Capital Partners, Cayuga Venture Fund +4	20 Oct 2015
Debt Financing	Undisclosed	1	Advantage Capital Partners	18 Jun 2015
Debt Financing	Undisclosed	1	Advantage Capital Partners	01 Jul 2014
Venture Round	$14.00M	2	Cayuga Venture Fund, Rand Capital	11 Jun 2014
Venture Round	$12.00M	2	Cayuga Venture Fund, Rand Capital	19 Dec 2013
Debt Financing	$2.00M	1	Gefinor Capital	13 Dec 2013
Series A	Undisclosed	1	Advantage Capital Partners	25 Oct 2013
Venture Round	$6.00M	-		09 Feb 2012
Series A	$12.60M	1	Cayuga Venture Fund	24 May 2010

Funding Stage

Amount

Investors

Lead Investors

Date

Convertible Note

Undisclosed

Advantage Capital Partners

13 Feb 2019

Venture Round

$28.60M

Advantage Capital Partners, Cayuga Venture Fund +4

20 Oct 2015

Debt Financing

Undisclosed

Advantage Capital Partners

18 Jun 2015

Debt Financing

Undisclosed

Advantage Capital Partners

01 Jul 2014

Venture Round

$14.00M

Cayuga Venture Fund, Rand Capital

11 Jun 2014

Venture Round

$12.00M

Cayuga Venture Fund, Rand Capital

19 Dec 2013

Debt Financing

$2.00M

Gefinor Capital

13 Dec 2013

Series A

Undisclosed

Advantage Capital Partners

25 Oct 2013

Venture Round

$6.00M

09 Feb 2012

Series A

$12.60M

Cayuga Venture Fund

24 May 2010

FAQ About Rheonix, Inc

Improving standards of care by making molecular diagnostics available to more people, in more places, more often.

Rheonix, Inc was founded in 2007.

Rheonix, Inc is headquartered in Ithaca, United States.

Rheonix, Inc operates in Biotechnology, Health Care, Medical Devices and Privacy and Security. Its work centres on molecular diagnostics, biomedical device, Encompass platform and Rheonix CARD.

Rheonix, Inc has approximately 27 employees.

Rheonix, Inc has completed 11 funding rounds, raising a total of $86.72M. The latest funding stage is Convertible Note.

Top alternatives and competitors to Rheonix, Inc include Hememics Biotechnologies, Inc., SeqOne, Abionic, iFirst Medical Technologies, Invivoscribe. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Rheonix, Inc and Hememics Biotechnologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Rheonix, Inc

Funding Rounds & Investors (11)

Rheonix, Inc Alternatives & Competitors

FAQ About Rheonix, Inc